Scientific AmericanGene Therapy Is Now Available, but Who Will Pay for It?Scientific AmericanLONDON (Reuters) – The science of gene therapy is finally delivering on its potential, and drugmakers are now hoping to produce commercially viable medicines a… Continue reading
Gene therapies getting closer to delivering on promiseSeeking AlphaReuters reports that the time is fast approaching for gene therapies to deliver on their much-ballyhooed promise (therapeutically and commercially), especially since the first two out t… Continue reading
Protein Cages May Have Applications in Nanotechnology and Synthetic BiologyControlled Environments MagazineA multidisciplinary team from the Bristol BioDesign Institute has come together to study the self-assembly of protein building into protein cages… Continue reading
Singularity Hub |
Biocomputers Made From Cells Can Now Handle More Complex Logic
Singularity Hub But synthetic biology promises far more than just a party trick—by tinkering with a cell’s RNA repertoire, scientists may one day coax them to photosynthesize, produce expensive drugs on the fly, or diagnose and hunt down rogue tumor cells. |
WeeklyHub |
Protea, Mass General Partner on Cancer Immunotherapy Tests
GenomeWeb Under the terms of the deal, Protea will work with MGH’s Vaccine and Immunotherapy Center to develop a diagnostic methodology for obtaining cancer cell molecular profiles, including the distribution of drugs within cancer cells and molecular response … Protea Announces Research Agreement with Mass General HospitalMarkets Insider |
|
ATCC® Answers World Health Organization’s Call To Arms In The Race Against Antimicrobial Resistance
PR Newswire (press release) The ATCC Center for Translational Microbiology is a center of excellence created by ATCC and ILSE to focus on key challenges in current translational microbiology, including antimicrobial resistance, synthetic biology, microbial bioinformatics, and the … |